Stella Davies, MBBS, PhD, MRCP, tells how collaboration has elevated bone marrow transplant outcomes in children and adults.

Panelists, including Julie Kanter, MD, point to examples of gene editing advancements, savvy intellectual property plans and teamwork.

Experts discuss the potential impact of innovative engineered immune cells and other emerging approaches.

Experts consider how the advent of post-transplant cyclophosphamide (PTCy) has driven guideline changes and opened new possibilities.

Chair Christopher Hourigan, DM, DPhil, FRCP, discusses the potential for better understanding the diversity of cells that make HSC transplant successful.

Speakers highlight real-world success in increasing treatments and note possible solutions for obstacles ahead.

Speakers detail novel studies and methods to reduce the need for patient- or donor-derived cells.

Panelist Wasay Khan, MD, PhD, explains why integrating artificial intelligence comes with hurdles.

Chair Caroline Diorio, MD, leads a panel to examine increased understanding of the biology of CAR T-induced toxicities.

Brian Shaffer, MD, previews a session on cyclophosphamide, gut microbiota and T-cell depleted transplantation.